Notably, overactivation of cyclin-dependent kinase 4/6 (CDK4/6) promotes tumor cell proliferation and contributes to immune resistance, whereas the therapeutic use of CDK4/6 inhibitors (e.g., Palbociclib, Ribociclib, Abemaciclib) has been demonstrated to foster CD8+ T lymphocyte infiltration[19], suggesting their potential in combination therapies. Here, CDK4 is linked to neoplasm.